Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corp

J.P. Morgan analyst Ankur Rudra maintained a Buy rating on Tech Mahindra Limited on July 21 and set a price target of INR1,700.00. According to Tip...

J.P. Morgan Remains a Buy on Tech Mahindra Limited (TECHM)

In a report released on July 17, Akshat Agarwal from Jefferies maintained a Sell rating on Tech Mahindra Limited, with a price target of INR1,260.0...

Jefferies Reaffirms Their Sell Rating on Tech Mahindra Limited (TECHM)

Deven Choksey analyst maintained a Buy rating on Tech Mahindra Limited yesterday and set a price target of INR1,726.00. The company’s shares closed...

Deven Choksey Remains a Buy on Tech Mahindra Limited (TECHM)

In a report released today, Bhupendra Tiwary from ICICI Securities maintained a Buy rating on Tech Mahindra Limited, with a price target of INR1,80...

Tech Mahindra Limited (TECHM) Gets a Buy from ICICI Securities

Stockholm Nordtech Group AB ( ($SE:NTECH) ) has shared an update. Nordtech Group AB will present its interim report for the second quarter of 2026 ...

Nordtech schedules Q2 2026 interim report presentation for July 24

Stockholm Nordtech Group AB ( ($SE:NTECH) ) has issued an announcement. Stockholm Nordtech Group AB reported that the stabilisation period for its ...

Nordtech Ends Share Stabilisation Early as Over-Allotment Option Partially Exercised

The latest update is out from Tech Mahindra Limited ( ($IN:TECHM) ). Tech Mahindra’s Brazilian subsidiary has signed a Quota Purchase Agreement wit...

Tech Mahindra to acquire Brazilian IT firm Alyis to bolster Orange partnership in LATAM

In a report released yesterday, Ankur Rudra from J.P. Morgan maintained a Buy rating on Tech Mahindra Limited, with a price target of INR1,600.00. ...

New Buy Rating for Tech Mahindra Limited (TECHM), the Technology Giant

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Techne (TECH), Concentra Group Holdings Parent...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)

Stockholm Nordtech Group AB ( ($SE:NTECH) ) just unveiled an announcement. Stockholm Nordtech Group AB has updated its share capital structure foll...

Nordtech Updates Share Capital After Nasdaq Stockholm Listing

An update from Tech Mahindra Limited ( ($IN:TECHM) ) is now available. Tech Mahindra has notified the stock exchanges that it will hold a quarterly...

Tech Mahindra Schedules Q1 FY27 Earnings Call for Analysts and Investors

Stockholm Nordtech Group AB ( ($SE:NTECH) ) has issued an update. Stockholm Nordtech Group AB, whose ordinary shares are listed on Nasdaq Stockholm...

Nordtech discloses post-IPO share price stabilisation on Nasdaq Stockholm

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX) and Bio-Techne (TECH) wit...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TECH	$71.60	-0.24%	2.07M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TECH	$71.60	-0.2%	2.07M
3
4
5
6

TECH

TECH

Get Bio-Techne Corp Data in Excel

Get Bio-Techne Corp Data in Excel